Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
复制标题
晚期非小细胞肺癌(NSCLC)免疫治疗反应和毒性的循环生物标志物：综述。
DOI：
10.3390/cancers13081794
复制
发表时间：
2021-04-09
期刊：
影响因子：
5.2
通讯作者：
Grossi F
中科院分区：
文献类型：
--
作者：
Indini A;Rijavec E;Grossi F
Although immunotherapy has dramatically revolutionized non-small cell lung cancer (NSCLC) treatment, not all the patients will benefit from this innovative therapy. The identification of potential biomarkers able to predict efficacy and toxicity of immunotherapy represents an urgent need for tailored treatment regimens. Liquid biopsy is a minimally invasive and economical tool that could provide important information about patients’ selection and treatment monitoring. Currently, several blood biomarkers are under investigation (circulating immune and tumor cells, soluble immunological mediators, peripheral blood cells). Prospective clinical trials are needed to validate their use in clinical practice. Immune checkpoint inhibitors (ICIs) targeting the programmed cell death (PD)-1 protein and its ligand, PD-L1, and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, have revolutionized the management of patients with advanced non-small cell lung cancer (NSCLC). Unfortunately, only a small portion of NSCLC patients respond to these agents. Furthermore, although immunotherapy is usually well tolerated, some patients experience severe immune-related adverse events (irAEs). Liquid biopsy is a non-invasive diagnostic procedure involving the isolation of circulating biomarkers, such as circulating tumor cells (CTC), cell-free DNA (cfDNA), and microRNAs (miRNAs). Thanks to recent advances in technologies, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), liquid biopsy has become a useful tool to provide baseline information on the tumor, and to monitor response to treatments. This review highlights the potential role of liquid biomarkers in the selection of NSCLC patients who could respond to immunotherapy, and in the identification of patients who are most likely to experience irAEs, in order to guide improvements in care.
登录
查看更多内容
影响因子：
4.6
作者：
Dhar M;Wong J;Che J;Matsumoto M;Grogan T;Elashoff D;Garon EB;Goldman JW;Sollier Christen E;Di Carlo D;Kulkarni RP
通讯作者：
Kulkarni RP
影响因子：
3.9
作者：
Alama, Angela;Coco, Simona;Grossi, Francesco
通讯作者：
Grossi, Francesco
影响因子：
4.9
作者：
Boutsikou E;Domvri K;Hardavella G;Tsiouda D;Zarogoulidis K;Kontakiotis T
通讯作者：
Kontakiotis T
影响因子：
5.2
作者：
Castello, Angelo;Carbone, Francesco Giuseppe;Lopci, Egesta
通讯作者：
Lopci, Egesta
影响因子：
2.8
作者：
Chang Y;Tolani B;Nie X;Zhi X;Hu M;He B
通讯作者：
He B